NCT00165308

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

A Feasibility Study of Tamoxifen Prevention of Breast Cancer in Hodgkin's Disease Survivors

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: Female
• Age: 18 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is determine whether or not tamoxifen reduces the chance of Hodgkin's Disease survivors developing breast cancer.

Detailed description

* Patients will receive tamoxifen orally once daily to be taken at home for 1 year. They will be asked to complete a daily drug log to keep track of the pills taken or missed. * Patients will also be asked to give a blood/DNA sample which will be stored for possible further testing for the presence of cancer related genes that are known nor or discovered in the future. * Patients will also receive a mammogram that will be reviewed by study officials. * Side effects will be monitored every 2 months for one year, between visits to the clinic. * A follow-up visit will be conducted at the 6 month mark and includes a physical exam, blood work, health and wellness surveys) * A follow-up visit will be performed at the 1 year mark and includes a mammogram, gynecological exam, physical exam, blood work, health and wellness surveys. * Patients active participation will be for 1 year. However, tamoxifen has been shown to be effective after a 5-year course in other women at increased risk for breast cancer, the patient may decide to stay on tamoxifen for 4 additional years.

Conditions

• Hodgkin's Disease
• Breast Cancer

Interventions

Type	Name	Description
DRUG	Tamoxifen	Given orally, daily for one year.

Timeline

• Start date: 2001-04-01
• Primary completion: 2004-03-01
• Completion: 2009-06-01
• First posted: 2005-09-14
• Last updated: 2014-07-09

Locations

2 sites across 1 country: United States